Immune / inflammation peptides
Thymic, antimicrobial, and immune-modulating peptides studied for immune activity and inflammation.
S is approval-grade evidence; F is documented harm or near-zero human data. Each bar is how many peptides on this page land in that tier — a fast read on how much of this category sits in approval-grade evidence versus thin or vendor-driven claims.
The category at a glance
Every compound here ranked S–F by its weighted evidence score — strongest human / approval-grade evidence at the top, thin or vendor-driven claims at the bottom. Tap any row for the evidence read. Popularity never raises a tier.
Receipts, not vendor theater. Every tier here is computed from published evidence and regulatory status — not vendor marketing or influencer claims. See how we score.
Cthymosin-alpha-1Moderate human evidenceLow overstatementInvestigational56/ 100
A synthetic immunomodulatory peptide (Zadaxin / thymalfasin) approved in several countries for chronic hepatitis B/C and as an immune adjuvant — though not FDA-approved in the US. It has a substantial real clinical base, including randomized controlled trials in chronic hepatitis B; results vary by indication.
Tier read: moderate human evidence · low overstatement risk · low search interest · Clinical trials. Why not D: supported by its overall evidence profile. Why not B: held back by remaining gaps and limited replication.
Read the full thymosin-alpha-1 profile →CvipModerate human evidenceLow overstatementResearch-use-only50/ 100
An endogenous neuropeptide with pulmonary-vasodilatory and anti-inflammatory properties, investigated for pulmonary arterial hypertension (and as the analogue aviptadil). Evidence is largely preclinical or early-phase; an early study reported improvement with inhaled VIP, but later controlled trials were mixed/modest.
Tier read: moderate human evidence · low overstatement risk · low search interest · Early human. Why not D: supported by mechanism confidence. Why not B: held back by safety clarity, regulatory clarity, practical relevance.
Read the full vip profile →Fll-37Early human evidenceMedium overstatementResearch-use-only34/ 100
The active form of the human cathelicidin antimicrobial peptide — an endogenous host-defence molecule with antimicrobial, immunomodulatory and wound-healing activity. The evidence base is predominantly preclinical with only early-stage human research; not an approved drug.
Tier read: early human evidence · medium overstatement risk · low search interest · Animal. Why not D: held back by human evidence, safety clarity, regulatory clarity, practical relevance.
Read the full ll-37 profile →FkpvEarly human evidenceMedium overstatementResearch-use-only28/ 100
A short tripeptide derived from α-MSH studied for anti-inflammatory activity, largely in preclinical models. Human clinical evidence is minimal and it is not approved.
Tier read: early human evidence · medium overstatement risk · low search interest · Animal. Why not D: held back by human evidence, safety clarity, regulatory clarity, practical relevance.
Read the full kpv profile →Immune and inflammation peptides span thymic, antimicrobial, and immune-modulating compounds. A couple are approved outside the US for specific conditions; most are research-only with limited human data.
Start with the best-supported options first: thymosin-alpha-1. Then compare them before exploring research-only compounds.
- This immune / inflammation overview (you're here)
- thymosin-alpha-1
- Safety & quality guide
What the evidence actually supports
Thymosin alpha-1 modulates T-cell function and is approved in some countries (not the US) for hepatitis B/C and as an immune adjuvant. LL-37 (a host-defense peptide), KPV (an α-MSH fragment), and VIP are studied for antimicrobial and anti-inflammatory activity, largely preclinically.
Where the hype outruns the data
“Boosts immunity” in healthy people, curing or preventing disease, and replacing vaccines or treatment are not supported. Immune modulation is double-edged — LL-37, for instance, can be pro-inflammatory in some settings.
FAQ
Do immune peptides boost immunity?
“Boosting immunity” in healthy people isn't an established benefit; immune modulation can cut both ways.
Is thymosin alpha-1 approved?
It's approved in several countries for specific uses, but not FDA-approved in the US.
Is this medical advice?
No — research reference only.
Research reference only. Not medical advice, dosing, or a recommendation to use any compound. “Worth watching” ≠ proven or safe.